Jonathan Silberstein MD, MBA
Chief of Urologic Oncology, Memorial Health System, Broward, FloridaBiographical Sketch:
Jonathan Silberstein earned his medical degree at SUNY Upstate Medical University in Syracuse, New York. He completed his general surgery internship and his urology residency at the University of California in San Diego. Following his residency, Dr. Silberstein completed a 3-year fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center in New York. He joined the faculty of Tulane University School of Medicine in 2013 and was the Director of Urologic Oncology at Tulane and the Assistant Chief of Urology at the Southeast Louisiana Veterans Affairs Hospital. He is the author of more than 60 peer-reviewed publications and several book chapters.He is now the Chief of Urologic Oncology Memorial Health System, Broward Florida.
He is also the winner of numerous awards from national and international meetings and is a reviewer for several prominent urologic journals.
Positions:
Assistant Professor of Urology; Chief, Section of Urologic Oncology, Department of Urology, Tulane University School of Medicine; Chief of Urology Service, Department of Surgery, Southeast Louisiana Veterans Health Care Center, New Orleans, Louisiana
Degrees:
MD: SUNY Upstate Medical University, Syracuse, New York
Postgraduate Training:
Fellowship (urologic oncology): Memorial Sloan Kettering Cancer Center, New York, New York
Clinical Interests:
Advanced urologic malignancies
Research Interests:
Clinical trial design and implementation, 3D printing physical models of urologic malignancies
Recent Contributions to PracticeUpdate:
- Combined EBRT and Brachytherapy vs Radical Prostatectomy With Adjuvant Radiation Therapy for Prostate Cancer
- Short-Term ADT Combined With Radiotherapy as Salvage Treatment After Radical Prostatectomy
- GnRH-Agonist vs GnRH-Antagonist Among Patients With Advanced Prostate Cancer and Pre-Existing CVD
- ESMO 2018: Recommendations From Dr. Jonathan Silberstein
- Role of Biomarkers in Therapy Selection for Upfront Hormone-Sensitive Prostate Cancer
- Review of Clinically Relevant New Research in Prostate Cancer
- Evolving Role of PSA Screening in Prostate Cancer
- Effect of Decreased Screening on Prostate Cancer Patient Presentation
- Oligometastatic Disease: Surgical Extirpation and Treatment of Metastatic Lesions
- The Role of HOXC6 in Prostate Cancer Development